Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
alt text
sign up
C4X Discovery Holdings Ltd
Company Name:C4X Discovery Holdings Ltd Minimum fundraise:£0.00* High Share Price Bid:£0.12
Business Sector:Pharmaceuticals, healthcare and biotechnology Total Funds Bid to Date:£1,000,000.00 Low Share Price Bid:£0.05
Auction period:17 Feb 2025 - 08 May 2025 Indicative Share Price:4.50 Average Share Price Bid:£0.08**
Company Details Below
*The company will accept oversubscription.
**In the event of significant oversubscription, shares will be allocated to bids at the average price and above.
NOTE: ASSET MATCH HAS NEGOTIATED AN “ASSET MATCH INVESTOR BONUS” FOR INVESTORS IN THIS TRANSACTION. SEE THE “OVERVIEW” SECTION BELOW FOR DETAILS.

Need help?
+44 (0) 207 248 2788

back

C4X Discovery Holdings Ltd

C4X Discovery Holdings Ltd

Market Cap: £11,493,101 Auction period: 17 Feb 2025 - 08 May 2025 Indicative price: 4.50

Live Started 73 days ago

Current Indicative Price 4.50p

Auction closes in 7 days


BUY ORDERS SELL ORDERS

BuyersShares Wanted Total Wanted Share Price (p)
-- -- 1,000,000 4.00
1 1,000,000 1,000,000 4.50
       
Share Price (p) Total Offered Shares OfferedSellers
4.00 668,900 668,900 4
4.50 708,900 40,000 2
       

BUY ORDERS

SELL ORDERS

Buyers Shares Total Shares Share Price (p) Total Shares Shares Sellers
-- -- 1,000,000 4.00 668,900 668,900 4
1 1,000,000 1,000,000 4.50 708,900 40,000 2
             

Interested in C4X Discovery Holdings Ltd?
Register or log in to participate, create a watchlist, or set reminder

Register Log in

Company info

C4X Discovery Holdings Ltd (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. Our internal portfolio of discovery programmes is advancing towards clinical trials with one programme in the pre-clinical candidate selection stage. We have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.

www.c4xdiscovery.com

Auction Details

The Ordinary Shares of C4X Discovery Holdings Ltd were admitted to trading on Asset Match on 26 April 2024 at a price of 12 pence per share (being the last traded price on AIM).

Auctions are to be held quarterly and close at 4pm on the second Thursday of each month (unless stated otherwise).

The tick size for this company is 0.25 pence per share.

Participants can send orders via their existing broker or directly to shareDeal active. Further details can be found by clicking on the "Auction instructions" section below.

Trading History (last 10)

Enlarge

Auction instructions

To buy and sell shares in this company via Asset Match Private Market, you will need to use a stockbroker.

           -  shareDeal active

If you are a UK resident, our main broker and settlement agent for all CREST eligible companies on the AM Private Market is shareDeal active.

shareDeal active provide a competitively priced service for both certified and non-certified transactions. You can open an account online or by post using the form provided.

Alternatively, if you already have an account with shareDeal active and wish to place an order please contact the Dealing desk directly on 01892 510515 or deal online.

To sell a share certificate, the easiest way to trade is to set up a shareDeal active account online and once open post your share certificate with a completed CREST transfer form. Alternatively, you can open an account by post using the Asset Match Certificated Sale Pack which includes everything you will need.

It generally takes 5-7 days for your account to be open and shares available for trading.

           -  Already have a stockbroker

Over 60 UK brokers regularly trade and are set up to deal on our platform. These brokers can submit your instructions to shareDeal active on your behalf*.

Please note that not all brokers are able to deal in unquoted shares so contact us to confirm whether your broker is able to trade.

           -  Overseas

If you are based overseas and are interested in participating then please contact us directly by emailing dealing@assetmatch.com or by calling 020 7248 2788.

​​When buying and selling shares, please note that the Asset Match levy of 3% applies, with a minimum charge of £20 per trade (*additional fees may apply).

For more information on how the auction works then please click here.

 

Key People

David

David Lawrence Interim Non-Executive Chairman

David joined C4XD in December 2024. He is currently a Non-Executive Director at EnteroBiotix, a UK private, clinical-stage microbiome company, and Glen Clova Scientific, a UK private biotech creating a new class of active biologics. He began his career at GSK and has held senior and executive roles at leading companies such as Chiron Vaccines which was acquired by Novartis and Acambis which was acquired by Sanofi and Valneva, where he led its US IPO. David also co-founded Synpromics, a synthetic biology company, where he recruited the senior management team and the Board; Synpromics was acquired by Ask Bio in 2019.
   
Emma

Emma Blaney PhD Interim CEO

Emma has been Interim CEO since January 2025 and leads the business with responsibility for defining and implementing strategy, ensuring its continued growth focused on the development of new and innovative immuno-inflammatory therapeutics. As a trained medicinal chemist, Emma joined C4XD in 2014 as a Senior Programme Manager and has gained more than 18 years’ experience working on Drug Discovery programmes within the Pharmaceutical sector. She brings extensive project management experience to the Executive Team with a particular focus on outsourcing management and collaborations. Previously she was a Section Head at Peakdale Molecular leading multiple projects for pharmaceuticals clients and a Medicinal Chemistry Team Leader at GSK within the Neurology and Gastrointestinal Department. Emma has a PhD in Synthetic Organic Chemistry from the University of Leeds, and a first-class Chemistry and Pharmacology degree from the University of Liverpool.
   
Julian

Julian Lord Interim Chief Financial Officer

Julian has 20 years’ experience in the life sciences industry and joined C4XD in December 2024. He is also CFO at Edinburgh Molecular Imaging, a clinical stage company developing a c-Met targeted radioligand therapy. Julian was previously CFO at Caldan Therapeutics and Group Financial Controller at Mereo BioPharma Group, working on establishing and growing the finance function and successful listings on AIM and Nasdaq. Prior to Mereo, he was Financial Controller at Immune Targeting Systems (ITS) Ltd from 2010 through to its merger with Vaxin Inc in 2015. Julian holds a BA (Hons) from Durham University and is a qualified management accountant (ACMA, CGMA).
   
Nick

Nick Ray PhD Chief Scientific Officer

Nick oversees the C4XD Drug Discovery portfolio from target selection through to pre-clinical candidate generation and partnering alongside Dr. Clare Murray, SVP Drug Discovery. Nick also leads the medicinal chemistry, structural analysis and computational chemistry/cheminformatics teams and together, with our CTO Dr Charles Blundell, is leading the continued development of our conformational analysis technology, 4Sight. Nick joined C4XD in 2016 and has more than 30 years’ experience leading key programmes at large multi-national companies including Rhône-Poulenc, Celltech and Argenta/Charles River, in the therapeutic areas of oncology, respiratory diseases, inflammation, CNS, pain and metabolic diseases. Eight of these programmes have progressed into the clinic to date. As head of the chemistry department at Charles River’s Harlow U.K. site, Nick was responsible for more than 70 chemists, fostering both the importance of strong medicinal and synthetic chemistry skills and championing professional development for his team, winning the Royal Society of Chemistry Retrosynthesis competition in 2015. He is a named inventor on over 75 patents and patent applications and has published 21 papers and presentation abstracts. Nick holds a PhD in organic chemistry from the University of Birmingham, UK.
   
Bhavna

Bhavna Hunjan Chief Business Officer

Bhavna has spent almost 15 years in commercial and corporate roles, first as an investment banker at Lehman Brothers and Nomura International and then in corporate strategy at PwC and Cancer Research UK. In 2016, she was hired by C4XD to incept and establish a new team focused on business development, deal structuring and execution, commercial intelligence, financing, and strategic planning / M&A. Since then, Bhavna has led this team to execute a series of successful licensing deals and strategic partnerships, as well as driving business growth and capital raising as part of the Executive Management team. Bhavna has a first class Masters degree in Biochemistry from the University of Oxford. She was awarded a Rising Star in the Movers & Shakers in BioBusiness 2017, and also voted one of the 30 Rising Leaders in Life Sciences 2020 by In Vivo.
   
Harmesh

Harmesh Suniara Non-Execuive Director

Harmesh has over 15 years’ experience of working in investment management, with a particular focus on UK small and mid-cap equities including the technology and life sciences sectors. He brings a wealth of expertise in active engagement with companies that Lombard Odier has invested in. He has worked as a Portfolio Manager at Lombard Odier 1798 Volantis since 2017, and prior to this he was an Investment Manager at Henderson Volantis Capital and Gartmore Investment Management. Harmesh graduated in Physics from the University of Cambridge. Lombard Odier 1798 Volantis is a major shareholder in C4X Discovery.
   
Richard

Richard Jones Non-Executive Director

Richard Jones is an experienced healthcare and life sciences Director. He was most recently CFO of Medica Group, a PE backed international tele-medicine business which was taken private in a £270m deal by IK partners from the UK main market; and is currently SID and Chair of the Audit Committee at Alliance Pharma PLC, an AIM listed consumer healthcare company. Richard previously gained extensive experience in the healthcare sector as CFO at UK AIM Listed companies Mereo BioPharma Group PLC and Shield Therapeutics PLC. At Mereo, he had a leading role in the merger with US listed OncoMed Pharmaceuticals, Inc and its subsequent dual listing on Nasdaq in 2019. At Shield, he established the finance operations and guided the company through several private financing rounds and its 2016 IPO. Prior to his CFO roles, Richard held senior investment banking positions at Investec and Brewin Dolphin Securities, where he advised healthcare clients on a wide range of transactions and fundraisings including IPOs, M&A and fundraisings. Richard qualified as a Chartered Accountant with PwC.
   
Shilina

Shilina Roman SVP Drug Discovery

Shilina Roman is SVP Drug Discovery and a member of the Executive Team. Shilina manages the biology team and oversees all aspects of drug discovery across the drug discovery portfolio. Prior to joining C4XD, Shilina was Senior Director, Head of Biology and Translational Medicine at Eliem Therapeutics, leading the biology and scientific strategy on project teams. Having started as a research scientist at GSK and Argenta Discovery, Shilina has significant experience in the drug discovery process from target identification through to phase 2 clinical trials, she held senior management roles at Charles River Laboratories and Eliem Therapeutics. Shilina has a B.Sc (Hons) in Biochemistry and Pharmacology from Kings College, London and a Diploma in Advanced Pharmacology from the British Pharmacological Society, with more than 15 published papers.